Komori
Governance4882Perseus Proteomics Inc.Pharmaceuticals

Notice Regarding Partial Amendments to the Articles of Incorporation

The Articles of Incorporation will be amended to expand the Company's business purposes, increase the total number of authorized shares from 24,000,000 to 50,000,000, permit the holding of virtual-only shareholders meetings, and enable the Board of Directors to make decisions on dividends of surplus and other matters. In addition, the term of office for additional directors and the method for selecting full-time Audit and Supervisory Committee Members will be changed.

Worth reading
55In focus
Scored from 2 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
50000000
Total number of authorized shares
Wording
Conditional
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Committee1
Audit and Supervisory Committee
Changes this time

Addition and reorganization of business purposes, increase in the total number of authorized shares from 24,000,000 to 50,000,000, introduction of provisions concerning shareholders meetings without a designated location, introduction of provisions concerning the terms of office for additional and substitute directors, change from “shall select” to “may select” a full-time Audit and Supervisory Committee Member, and introduction of provisions concerning the decision-making body for dividends of surplus and other matters.

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
CommitteeAudit and Supervisory Committee (proportion of outside members: Not disclosed)
Changes this timeAddition and reorganization of business purposes, increase in the total number of authorized shares from 24,000,000 to 50,000,000, introduction of provisions concerning shareholders meetings without a designated location, introduction of provisions concerning the terms of office for additional and substitute directors, change from “shall select” to “may select” a full-time Audit and Supervisory Committee Member, and introduction of provisions concerning the decision-making body for dividends of surplus and other matters.
Items this document does not state (5)
Number of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To respond to the future expansion and diversification of the Company's business domains, implement flexible capital and dividend policies, clarify the terms of office for additional and substitute directors, establish an environment that enables effective audits even when no full-time Audit and Supervisory Committee Member is selected, and reduce the risks associated with holding shareholders meetings while making them easier to attend, more active and more efficient.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Partial Amendments to the Articles of Incorporation | Perseus Proteomics Inc. (4882) timely disclosure | Komori